SCHEMBL23770595

SCHEMBL23770595

Cc1ccccc1-c1nc(NSc2cccc(N)n2)ccc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
MAPK14 Q16539 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
CTSD P07339 1/20 0.33
BACE1 P56817 1/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C19 P33261 2/20 0.33
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32
EPHA4 P54764 1/20 0.32
DPP4 P27487 2/20 0.32
GAA P10253 2/20 0.32
HSP90AA1 P07900 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770571 0.90 NOS3 (0.33) NOS3NOS2
SCHEMBL23770575 0.89 ADORA2A (0.37) ADORA2ACTSDBACE1ALDH1A1CYP1A2
SCHEMBL23770600 0.86 ALOX5AP (0.35) ALOX5APFEN1
SCHEMBL23770590 0.85 ADORA2A (0.35) ADORA2ACTSDBACE1EPHA4DPP4
SCHEMBL23770676 0.85 ADORA2A (0.35) ADORA2ACTSDBACE1ALDH1A1EPHA4
SCHEMBL23770551 0.85 PTPN1 (0.36) ADORA2ACTSDBACE1ALDH1A1CYP1A2
SCHEMBL23770584 0.82 GABRA1 (0.34) ADORA2ACTSDBACE1EPHA4DPP4
SCHEMBL23770417 0.80 GAA (0.33) GAA
SCHEMBL23770633 0.80 PLA2G7 (0.36) MAPTBACE1ALDH1A1EPHA4DPP4
SCHEMBL23770415 0.80 ADORA2A (0.34) ADORA2ASMN1; SMN2TP53MAPTBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed